Young people living with cystic fibrosis: An insight into their subjective experience

The aim of this article is to explore the experiences of young people living with cystic fibrosis and the impact of these experiences on their compliance to treatment regimen. Thirty-one young adults participated in semi-structured interviews which were transcribed and the data collected analysed using interpretative phenomenology. Emerging themes underlined just how complex it is to manage life with a chronic illness as demanding as cystic fibrosis. A strong emphasis emerged from the participants about their desire to integrate into society and to be seen to be normal and this was seen as in conflict with some aspects of their recommended ongoing treatment. The findings suggested that complete compliance is rare and is affected by a multitude of factors, set within the context of each individual's unique life experience. Healthcare professionals need to understand, not just the objective medical condition in delivering care, but they also need to develop an insight into the subjective experience of living with illnesses such as cystic fibrosis. Their central concern should not be to maximise compliance but rather to support the making of informed decisions about broader lifestyles and health behaviours. © 2006 Blackwell Publishing Ltd

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors

We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. We discovered a noncovalent, nonpeptidic inhibitor scaffold with lead-like properties that is differentiated from current main protease inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry. We generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. All compound designs (>18,000 designs), crystallographic data (>490 ligand-bound x-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2400 compounds) for this campaign were shared rapidly and openly, creating a rich, open, and intellectual property–free knowledge base for future anticoronavirus drug discovery